Biomarkers Could Predict Bladder Cancer Progression

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

This video examines a study that used liquid biopsies to monitor disease progression in patients with bladder cancer.

In this video, Emil Christensen, a researcher at Aarhus University Hospital in Denmark, discusses a study that used liquid biopsies to monitor disease progression in bladder cancer patients.

The study examined the feasibility and utility of tracking FGFR3 and PIK3CA hotspot mutations in patients’ urine and plasma. Two patient cohorts were studied: one included patients with non–muscle invasive disease, the other included those with muscle-invasive disease.

The results of the study were presented at the 2017 American Association for Cancer Researcher (AACR) Annual Meeting, held April 1–5 in Washington, DC.

Related Videos
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Related Content
Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

April 15th 2024
Article

Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC

Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC

April 13th 2024
Article

A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.

Emerging Immunotherapy Approaches For Urothelial Cancer

Emerging Immunotherapy Approaches For Urothelial Cancer

February 4th 2019
Podcast

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

AZD1390/Radiation Yields Encouraging Efficacy, Safety in Glioblastoma

April 9th 2024
Article

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.

Adagrasib Combo Yields Encouraging Responses in KRAS G12C–Mutated CRC

April 9th 2024
Article

Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.